Edgewise Therapeutics, Inc. – NASDAQ:EWTX

Add to watchlist

$13.155

-15.58

-54.23%

Market closed

Open in 1 day

+28.19%

month

+28.19%

quarter

+137.52%

year

Market Cap	2.85B
Enterprise value	288.43M

P/E	-4.46
EV/Sales	N/A
EV/EBITDA	-4.57
Price/Sales	N/A
Price/Book	0.88
PEG ratio	0.42
EPS	-1.55

Revenue	N/A
EBITDA	-121.88M
Income	-105.85M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Edgewise Therapeutics Stock Forecast

M Q Y

Last Year

$46.25

Potential upside: 251.57%

Analysts Price target
Financials & Ratios estimates

Edgewise Therapeutics, Inc. (NASDAQ:EWTX): Profit margin
Jun 2023	0	-21.46M
Sep 2023	0	-25.71M
Dec 2023	2.25M	-30.14M	-1338.5%
Mar 2024	0	-28.52M

Edgewise Therapeutics, Inc. (NASDAQ:EWTX): Debt to assets
Jun 2023	330625000	19.17M	5.8%
Sep 2023	311364000	20.93M	6.72%
Dec 2023	340035000	21.20M	6.24%
Mar 2024	553806000	18.86M	3.41%

Edgewise Therapeutics, Inc. (NASDAQ:EWTX): Cash Flow
Jun 2023	-20.23M	3.44M	369K
Sep 2023	-22.05M	23.41M	-211K
Dec 2023	-26.83M	26.98M	52.98M
Mar 2024	-28.59M	-268.30M	241.07M

Edgewise Therapeutics alternative data

Edgewise Therapeutics
Employees

Edgewise Therapeutics, Inc. (NASDAQ:EWTX): Employee count
Aug 2023	67
Sep 2023	74
Oct 2023	74
Nov 2023	74
Dec 2023	80
Jan 2024	80
Feb 2024	80
Mar 2024	88
Apr 2024	88
May 2024	88
Jun 2024	92
Jul 2024	92

Edgewise Therapeutics
Hedge Funds Holdings Q1 2023

30.76% -69.24%

of EWTX is owned by hedge funds

47 -44

hedge funds hold EWTX stock

16.48M -50.10M

shares is hold by hedge funds

EWTX hedge funds holdings changes

Edgewise Therapeutics
Insider Trading

Edgewise Therapeutics, Inc. (NASDAQ:EWTX): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	909090	90000
Feb 2024	0	39835
May 2024	0	14241
Sep 2024	0	320244
Dec 2024	0	29709

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	24 Dec 2024	SEMIGRAN MARC officer: Chief Development Officer officer: Chief Development Offi..	Stock Option (Right to Buy)	29,709	$8.94	$265,598
Option	24 Dec 2024	SEMIGRAN MARC officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	29,709	$8.94	$265,598
Sale	24 Dec 2024	SEMIGRAN MARC officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	27,980	$29.66	$829,915
Sale	24 Dec 2024	SEMIGRAN MARC officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	1,729	$30.08	$52,008
Option	11 Oct 2024	CARRUTHERS R MICHAEL officer: Chief Fi..	Stock Option (Right to Buy)	70,000	$0.71	$49,700
Option	11 Oct 2024	CARRUTHERS R MICHAEL officer: Chief Fi..	Common Stock	70,000	$0.71	$49,700
Option	23 Sep 2024	MOORE JOHN R officer: General Counsel officer: General Counsel	Stock Option (Right to Buy)	20,922	$0.71	$14,855
Option	23 Sep 2024	MOORE JOHN R officer: General Counsel officer: General Counsel	Common Stock	20,922	$0.71	$14,855
Sale	23 Sep 2024	MOORE JOHN R officer: General Counsel officer: General Counsel	Common Stock	20,922	$27.63	$578,075
Option	20 Sep 2024	RUSSELL ALAN J director, officer..	Stock Option (Right to Buy)	75,000	$0.18	$13,500

EWTX insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application PYRIDAZINONE COMPOUNDS AND USES THEREOF Filling date: 11 Jun 2021 Issue date: 7 Apr 2022	11 Jun 2021	7 Apr 2022
Application	Application PYRIDAZINONE COMPOUNDS AND USES THEREOF Filling date: 23 Nov 2021 Issue date: 17 Mar 2022	23 Nov 2021	17 Mar 2022
Grant	Grant Utility: Pyridazinone compounds and uses thereof Filling date: 3 Nov 2020 Issue date: 1 Feb 2022	3 Nov 2020	1 Feb 2022
Grant	Grant Utility: Pyridazinone compounds and uses thereof Filling date: 3 Nov 2020 Issue date: 17 Aug 2021	3 Nov 2020	17 Aug 2021
Application	Application PYRIDAZINONE COMPOUNDS AND USES THEREOF Filling date: 3 Nov 2020 Issue date: 24 Jun 2021	3 Nov 2020	24 Jun 2021
Application	Application PYRIDAZINONE COMPOUNDS AND USES THEREOF Filling date: 3 Nov 2020 Issue date: 17 Jun 2021	3 Nov 2020	17 Jun 2021
Application	Application PYRIDAZINONE COMPOUNDS AND USES THEREOF Filling date: 3 Nov 2020 Issue date: 6 May 2021	3 Nov 2020	6 May 2021
Application	Application METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS Filling date: 20 Aug 2020 Issue date: 4 Mar 2021	20 Aug 2020	4 Mar 2021

Edgewise Therapeutics
Executives

Insider	Age	Compensation
Dr. Kevin Koch Ph.D. (1960) Pres, Chief Executive Officer & Director	65	$680,000
Dr. Alan J. Russell Ph.D. (1970) Co-Founder, Chief Scientific Officer & Director	55	$481,250
Mr. R. Michael Carruthers (1958) Chief Financial Officer	67	$386,010

Edgewise Therapeutics
Latest News

Tuesday, 17 December 2024
10:20	EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study	zacks.com
Monday, 16 December 2024
11:56	Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease	benzinga.com
06:00	Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)	businesswire.com
Thursday, 5 December 2024
14:32	Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research	businesswire.com
Tuesday, 26 November 2024
06:00	Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024	businesswire.com
Monday, 30 September 2024
12:12	Analysts Think There's Still Time To Get In On Edgewise	benzinga.com
Wednesday, 25 September 2024
11:50	Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge	benzinga.com
09:00	Analyst Think There's Still Time to Get in on Edgewise, Up 332%	marketbeat.com
Sunday, 22 September 2024
17:34	Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?	benzinga.com
Thursday, 19 September 2024
14:16	Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge	marketbeat.com
13:01	EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies	zacks.com
12:55	Why Edgewise Therapeutics Stock Is Up 50% on Thursday	fool.com
10:19	Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment	benzinga.com
09:22	Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip	investors.com
07:00	Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)	businesswire.com
Tuesday, 17 September 2024
16:01	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time	businesswire.com
Monday, 5 August 2024
14:38	Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal	seekingalpha.com
Tuesday, 30 July 2024
12:25	7 Small-Cap Stocks to Buy for Large-Scale Gains	investorplace.com
Wednesday, 17 July 2024
13:00	Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy	zacks.com
Friday, 10 May 2024
08:00	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024	Business Wire
Monday, 26 February 2024
10:56	Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know	Zacks Investment Research
Sunday, 11 February 2024
14:55	Insider Favorites: 7 Stocks with Bullish Buying Signals	InvestorPlace
Friday, 9 February 2024
10:56	Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?	Zacks Investment Research
Saturday, 27 January 2024
13:09	Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More	24/7 Wall Street
Wednesday, 24 January 2024
10:56	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet	Zacks Investment Research
Monday, 22 January 2024
15:11	Edgewise (EWTX) Rallies 35% on Issue of New Common Stock	Zacks Investment Research
Thursday, 28 December 2023
15:00	Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing	Seeking Alpha
Tuesday, 26 December 2023
17:21	Wedbush's Laura Chico talks biotech investing in 2024	CNBC Television
Tuesday, 5 September 2023
11:17	Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet	Zacks Investment Research
Tuesday, 2 May 2023
08:00	Edgewise Therapeutics to Present at Upcoming Investor Conferences	Business Wire

Ideas & Opinions

Seeking Alpha 29 May 2025

Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint
Seeking Alpha 31 Dec 2024

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
Seeking Alpha 28 Dec 2023

Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing
Seeking Alpha 31 Jan 2023

Edgewise Therapeutics: Solid Data, Decent Cash, Great Management Profile
Seeking Alpha 28 Mar 2021

US IPO Weekly Recap: Healthcare Shines In A 17 IPO Week

Frequently Asked Questions (FAQ)

What's the price of Edgewise Therapeutics stock today?

One share of Edgewise Therapeutics stock can currently be purchased for approximately $13.16.
When is Edgewise Therapeutics's next earnings date?

Unfortunately, Edgewise Therapeutics's (EWTX) next earnings date is currently unknown.
Does Edgewise Therapeutics pay dividends?

No, Edgewise Therapeutics does not pay dividends.
How much money does Edgewise Therapeutics make?

Edgewise Therapeutics has a market capitalization of 2.85B.
What is Edgewise Therapeutics's stock symbol?

Edgewise Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "EWTX".
What is Edgewise Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Edgewise Therapeutics?

Shares of Edgewise Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Edgewise Therapeutics's key executives?
Edgewise Therapeutics's management team includes the following people:
- Dr. Kevin Koch Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $680,000)
- Dr. Alan J. Russell Ph.D. Co-Founder, Chief Scientific Officer & Director(age: 55, pay: $481,250)
- Mr. R. Michael Carruthers Chief Financial Officer(age: 67, pay: $386,010)
Is Edgewise Therapeutics founder-led company?

Yes, Edgewise Therapeutics is a company led by its founder Dr. Alan J. Russell Ph.D..
How many employees does Edgewise Therapeutics have?

As Jul 2024, Edgewise Therapeutics employs 92 workers, which is 5% more then previous quarter.
When Edgewise Therapeutics went public?

Edgewise Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 26 Mar 2021.
What is Edgewise Therapeutics's official website?

The official website for Edgewise Therapeutics is edgewisetx.com.
Where are Edgewise Therapeutics's headquarters?

Edgewise Therapeutics is headquartered at 3415 Colorado Avenue, Boulder, CO.
How can i contact Edgewise Therapeutics?

Edgewise Therapeutics's mailing address is 3415 Colorado Avenue, Boulder, CO and company can be reached via phone at +30 37358373.
What is Edgewise Therapeutics stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Edgewise Therapeutics in the last 12 months, the avarage price target is $46.25. The average price target represents a 251.57% change from the last price of $13.16.

Edgewise Therapeutics, Inc.

edgewisetx.com

Exchange:

NASDAQ

Full time employees:

108

Industry:

Biotechnology

Sector:

Healthcare

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

+30 37358373

3415 Colorado Avenue
Boulder, CO 80303

CIK: 0001710072
ISIN: US28036F1057
CUSIP: 28036F105